VIGL — Vigil Neuroscience Share News
0.000.00%
Last trade - 00:00- $375.71m
- $288.60m
Brief: Vigil Neuroscience, Inc. Q2 EPS USD -0.52.
Brief: Vigil Neuroscience Reports Q1 2023 Financial Results And Provides Business Update
Brief: Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. To Board Of Directors
Brief: Vigil Neuroscience Inc Launches Alspaware To Provide Access To No-Cost Genetic Testing And Counseling For Adult-Onset Leukoencephalopathy With Alsp
Mizuho initiates coverage on Vigil with 'buy' on lead therapy potential
U.S. RESEARCH ROUNDUP- Cintas, Stryker, Zimmer Biomet Holdings
Vigil Neuroscience rises as FDA lifts partial hold on brain disease therapy
Brief: Vigil Neuroscience Inc Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing
Brief: Vigil Neuroscience Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Vigil Neuroscience Inc Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Brief: Vigil Neuroscience Appoints David Gray As Chief Scientific Officer, Announces Changes To Executive Team
Brief: Vigil Neuroscience Announces First Patient Dosed In The Ignite Phase 2 Clinical Trial To Evaluate VGL101 In Patients With ALSP
Brief: Vigil Neuroscience Reports Third Quarter 2022 Results
Brief: Vigil Neuroscience Announces Interim Results From Phase 1 Clinical Trial Evaluating Vgl101 In Healthy Volunteers
Brief: Vigil Neuroscience Receives FDA Fast Track Designation For Vgl101 For The Treatment Of Patients With Alsp
Biogen's strong Alzheimer's drug data may benefit Vigil Neuroscience - Jefferies
Brief: BVF Partners LP Reports 7.5% Passive Stake In Vigil Neuroscience Inc As Of August 16 - SEC Filing
Brief: Vigil Neuroscience announces $75 million private placement financing
Brief: Vigil Neuroscience reports Q2 results